Lantheus logged a 7.8% change during today's afternoon session, and is now trading at a price of $85.67 per share. The S&P 500 index moved -0.0%. LNTH's trading volume is 1,430,997 compared to the stock's average volume of 881,195.
Lantheus trades -36.07% away from its average analyst target price of $134.0 per share. The 11 analysts following the stock have set target prices ranging from $110.0 to $166.0, and on average have given Lantheus a rating of buy.
If you are considering an investment in LNTH, you'll want to know the following:
-
Lantheus's current price is 145.7% above its Graham number of $34.86, which implies that at its current valuation it does not offer a margin of safety
-
Lantheus has moved 11.6% over the last year, and the S&P 500 logged a change of 29.9%
-
Based on its trailing earnings per share of 6.02, Lantheus has a trailing 12 month Price to Earnings (P/E) ratio of 14.2 while the S&P 500 average is 29.3
-
LNTH has a forward P/E ratio of 12.4 based on its forward 12 month price to earnings (EPS) of $6.93 per share
-
Its Price to Book (P/B) ratio is 5.05 compared to its sector average of 3.53
-
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.
-
Based in Bedford, the company has 834 full time employees and a market cap of $5.96 Billion.
